Millennium Management Amends Kezar Life Sciences Stake
Ticker: KZR · Form: SC 13G/A · Filed: Jan 22, 2024 · CIK: 1645666
| Field | Detail |
|---|---|
| Company | Kezar Life Sciences, INC. (KZR) |
| Form Type | SC 13G/A |
| Filed Date | Jan 22, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, biotech, hedge-fund
TL;DR
**Millennium Management updated its stake in Kezar Life Sciences, signaling a potential shift in their investment thesis.**
AI Summary
Millennium Management LLC, a hedge fund led by Israel A. Englander, filed an amended SC 13G/A on January 22, 2024, disclosing its ownership of Kezar Life Sciences, Inc. common stock as of December 31, 2023. This filing indicates a change in their previously reported stake in Kezar Life Sciences, Inc. (KZR), a pharmaceutical preparations company. This matters to investors because it reveals a significant institutional investor's updated position, which can influence market sentiment and potentially signal their confidence or lack thereof in the company's future prospects.
Why It Matters
This filing shows an updated position from a major institutional investor, Millennium Management LLC, in Kezar Life Sciences, Inc., which can impact investor perception and stock price.
Risk Assessment
Risk Level: medium — While not inherently risky, changes in institutional ownership can precede significant stock movements, creating volatility.
Analyst Insight
Investors should monitor subsequent filings from Millennium Management LLC and other institutional investors to understand the evolving sentiment around Kezar Life Sciences, Inc. and consider the implications for their own investment thesis.
Key Players & Entities
- Millennium Management LLC (company) — reporting person and hedge fund
- Israel A. Englander (person) — group member associated with Millennium Management LLC
- Kezar Life Sciences, Inc. (company) — subject company, a pharmaceutical preparations firm
- December 31, 2023 (date) — date of event requiring the filing
- January 22, 2024 (date) — filing date of the SC 13G/A
- Delaware (company) — place of organization for Millennium Management LLC
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing under the Securities Exchange Act of 1934.
Who is the subject company of this filing?
The subject company is Kezar Life Sciences, Inc., with a CIK of 0001645666 and a business address at 4000 Shoreline Court, Suite 300, South San Francisco, CA 94080.
Who is the reporting person in this filing?
The primary reporting person is Millennium Management LLC, a company organized in Delaware with a business address at 399 Park Avenue, New York, NY 10022.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the common stock of Kezar Life Sciences, Inc. is 49372L100.
What was the date of the event that required this amendment filing?
The date of the event which required the filing of this statement was December 31, 2023.
Filing Stats: 1,548 words · 6 min read · ~5 pages · Grade level 10.2 · Accepted 2024-01-22 16:04:12
Key Financial Figures
- $0.001 — me of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securiti
Filing Documents
- KZR_SC13GA1_2024.htm (SC 13G/A) — 78KB
- 0001273087-24-000021.txt ( ) — 80KB
If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is
Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a: (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) o An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) o An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); CUSIP No. 49372L100 SCHEDULE 13G Page 6 of 10 (g) o A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) o Group, in accordance with 240.13d-1(b)(1)(ii)(J).
Ownership
Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: See response to Item 9 on each cover page. (b) Percent of Class: See response to Item 11 on each cover page. (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote See response to Item 5 on each cover page. CUSIP No. 49372L100 SCHEDULE 13G Page 7 of 10 (ii) Shared power to vote or to direct the vote See response to Item 6 on each cover page. (iii) Sole power to dispose or to direct the disposition of See response to Item 7 on each cover page. (iv) Shared power to dispose or to direct the disposition of See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Ownership of Five Percent or Less of a Class
Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following þ .
Ownership of More than Five Percent on Behalf of Another Person
Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable.
Identification and Classification of the Subsidiary Which Acquired
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not applicable.
Identification and Classification of Members of the Group
Item 8. Identification and Classification of Members of the Group See Exhibit I.
Notice of Dissolution of Group
Item 9. Notice of Dissolution of Group Not applicable.
Certification
Item 10. Certification By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. CUSIP No. 49372L100 SCHEDULE 13G Page 8 of 10 Exhibits: Exhibit I: Joint Filing Agreement, dated as of January 19, 2024, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. CUSIP No. 49372L100 SCHEDULE 13G Page 9 of 10 SIGNATURE After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct. Dated: January 19, 2024 MILLENNIUM MANAGEMENT LLC By: /s/Gil Raviv Name: Gil Raviv Title: Global General Counsel MILLENNIUM GROUP MANAGEMENT LLC By: /s/Gil Raviv Name: Gil Raviv Title: Global General Counsel /s/ Israel A. Englander Israel A. Englander CUSIP No. 49372L100 SCHEDULE 13G Page 10 of 10 EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.001 per share, of Kezar Life Sciences, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Dated: January 19, 2024 MILLENNIUM MANAGEMENT LLC By: /s/